# A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Source: https://onco.cc/trials/nct05319730/  
OnCo record `nct05319730` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Lenvatinib, Sacituzumab tirumotecan and Dexamethasone in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) is a phase 1/2 interventional study registered as NCT05319730 by Merck Sharp & Dohme LLC, with 230 participants planned, started 2023-05-16 and due to reach its primary completion in 2027-06-11. Interventions recorded: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib and Sacituzumab tirumotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05319730
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT05319730: https://clinicaltrials.gov/study/NCT05319730

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05319730.json